Breaking the mold: Overcoming resistance to immune checkpoint inhibitors

被引：3
|
作者：
Zhao, Menglu [1 ]
Yan, Chun-Yan [1 ]
Wei, Ya-Nan [1 ]
Zhao, Xi-He [1 ]
机构：
[1] China Med Univ, Shengjing Hosp, Dept Clin Oncol, Shenyang 110022, Peoples R China
来源：
ANTIVIRAL RESEARCH | 2023年 / 219卷
基金：
中国国家自然科学基金;
关键词：
PD-L1; Drug resistance; Bispecific antibody; Antibody drug conjugate (ADC); TUMOR MUTATIONAL BURDEN; T-CELLS; ANTITUMOR IMMUNITY; CANCER; IMMUNOTHERAPY; BLOCKADE; EFFICACY; RECEPTOR; PD-L1; EXPRESSION;
D O I：
10.1016/j.antiviral.2023.105720
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Immune checkpoint blockade-based therapies are effective against a sorts of cancers. However, drug resistance is a problem that cannot be ignored. This review intends to elucidate the mechanisms underlying drug tolerance induced by PD-1/PD-L1 inhibitors, as well as to outline proposed mechanism-based combination therapies and small molecule drugs that target intrinsic immunity and immune checkpoints. According to the differences of patients and types of cancer, the optimization of individualized combination therapy will help to enhance PD-1/ PD-L1-mediated immunoregulation, reduce chemotherapy resistance, and provide new ideas for chemotherapyresistant cancer.
引用
收藏
页数：11
相关论文
共 50 条
  • [1] Resistance to immune checkpoint inhibitors and the tumor microenvironment
    Kawashima, Shusuke
    Togashi, Yosuke
    EXPERIMENTAL DERMATOLOGY, 2023, 32 (03) : 240 - 249
  • [2] Mechanisms of resistance to immune checkpoint inhibitors
    Nagasaki, Joji
    Ishino, Takamasa
    Togashi, Yosuke
    CANCER SCIENCE, 2022, 113 (10) : 3303 - 3312
  • [3] Overcoming the resistance of pancreatic cancer to immune checkpoint inhibitors
    Skelton, Richard A.
    Javed, Ammar
    Zheng, Lei
    He, Jin
    JOURNAL OF SURGICAL ONCOLOGY, 2017, 116 (01) : 55 - 62
  • [4] Overcoming resistance to immune checkpoint inhibitors in hepatocellular carcinoma: Challenges and opportunities
    Xie, Qingqing
    Zhang, Pengfei
    Wang, Yuanyuan
    Mei, Wuxuan
    Zeng, Changchun
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [5] Biological mechanisms of resistance to immune checkpoint inhibitors and overcoming this resistance: Challenges in medical oncology
    Moskalenko, Y.
    REGULATORY MECHANISMS IN BIOSYSTEMS, 2024, 15 (01) : 83 - 91
  • [6] Mechanisms of resistance to immune checkpoint inhibitors
    Jenkins, Russell W.
    Barbie, David A.
    Flaherty, Keith T.
    BRITISH JOURNAL OF CANCER, 2018, 118 (01) : 9 - 16
  • [7] Overcoming Resistance to Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinomas
    dos Santos, Lucas, V
    Abrahao, Carina M.
    William, William N.
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [8] Immune Checkpoint Inhibitors in Prostate Cancer
    Venkatachalam, Shobi
    McFarland, Taylor R.
    Agarwal, Neeraj
    Swami, Umang
    CANCERS, 2021, 13 (09)
  • [9] Immune Checkpoint Inhibitors: Basics and Challenges
    Li, Bin
    Chan, Ho Lam
    Chen, Pingping
    CURRENT MEDICINAL CHEMISTRY, 2019, 26 (17) : 3009 - 3025
  • [10] Tumor microenvironment changes leading to resistance of immune checkpoint inhibitors in metastatic melanoma and strategies to overcome resistance
    Pulluri, Bhargavi
    Kumar, Abhijeet
    Shaheen, Montaser
    Jeter, Joanne
    Sundararajan, Srinath
    PHARMACOLOGICAL RESEARCH, 2017, 123 : 95 - 102
12345